Secukinumab, a monoclonal antibody targeting interleukin-17A, is effective for treating moderate-to-severe plaque psoriasis but may induce paradoxical inflammatory bowel disease, particularly Crohn’s disease. This evidence concerns the gene IL17A and inflammatory bowel disease.